Furthermore, PPAR-β/δ transgenic mice did not accumulate myocardial lipid and had a normal cardiac function which identifies PPAR-β/δ as a possible target metabolic modulation therapy for cardiac dysfunction in diabetes [5,101]. The gene discussed is PPARD; the disease is diabetes mellitus.